Artios Pharma

Artios Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class precision medicines for cancer by targeting the DNA Damage Response (DDR) pathway. The company leverages its proprietary DcoDeR platform to identify and develop small-molecule inhibitors that exploit synthetic lethality in cancer cells, particularly those with existing DNA repair deficiencies. Headquartered in Cambridge, UK, with a growing presence in the United States, Artios has established a concentrated pipeline of DDR programs. The company is advancing lead candidates such as alnodesertib (an ATR inhibitor) and ART6043 (a Polθ inhibitor) into late-stage clinical development, supported by strategic collaborations with major pharmaceutical partners like Merck KGaA and GSK.